Novo Nordisk A/S

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Novo Nordisk A/S - share repurchase programme - November 9, 2026

Share buyback AI-generated analysis

πŸ“Š Novo Nordisk executed DKK 8 billion in share repurchases between November 3-6, 2026, reducing outstanding B shares by approximately 1.3% of total capital.

πŸ’° The company has spent a cumulative DKK 11.8 billion on buybacks since the programme launched on February 4, 2026, averaging DKK 277.16 per share.

πŸ“… Under the current tranche ending February 1, 2027, Novo Nordisk has utilized roughly 73% of its authorized DKK 11.2 billion repurchase limit.

🏒 The company now holds 56.6 million B shares as treasury stock, maintaining compliance with European Market Abuse Regulation (MAR) guidelines.

πŸ“ˆ The buyback programme supports the broader strategy of returning capital to shareholders through its ADRs listed on the NYSE under ticker NVO.

🌍 Novo Nordisk continues its global expansion with 67,000 employees driving health innovations across multiple therapeutic areas.

Bullish Signals
  • Novo Nordisk is actively returning capital to shareholders through a structured share repurchase programme, having spent DKK 11.8 billion since February 2026.
  • The company has utilized over 73% of its authorized DKK 11.2 billion buyback limit for the current tranche, signaling confidence in its stock valuation and financial position.
  • Novo Nordisk maintains a strong treasury share position of 56.6 million B shares (1.3% of capital), demonstrating disciplined capital allocation strategies.
Full Analysis
Novo Nordisk A/S announced on November 9, 2026, that it has executed share repurchases under a programme initiated on May 6, 2026. The company purchased B shares for an accumulated value of DKK 8,008,013,722 between November 3 and November 6, 2026, with transaction prices ranging from DKK 268.07 to DKK 281.05 per share. As of the announcement date, Novo Nordisk holds a total of 56,644,876 B shares as treasury stock, representing 1.3% of its total share capital. The company has repurchased a cumulative total of 42,604,179 B shares since the programme began on February 4, 2026, spending DKK 11,808,013,711 at an average price of DKK 277.16 per share. The current repurchase initiative allows for up to DKK 11,200,000,010.45 in purchases until February 1, 2027, while the broader programme covers up to DKK 15 billion over a 12-month period starting February 4, 2026. These actions reflect the company's ongoing capital management strategy involving its B shares listed on Nasdaq Copenhagen and ADRs traded as NVO on the New York Stock Exchange. Novo Nordisk continues to operate globally with over 67,000 employees focused on developing treatments for lasting health. The share buyback activities are conducted in accordance with European Market Abuse Regulation (MAR) and Safe Harbour Rules, with detailed transaction data published on the company's official website.